X4 Pharmaceuticals
Clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Launch date
Employees
Market cap
€109m
Enterprise valuation
€26m (Public information from Sep 2024)
Share price
$0.708 XFOR
Cambridge Massachusetts (HQ)
Authorizing premium user...